Official Journal of
East European Branch of
CardiOncology Society
Barbara Sosnowska-Pasiarska, Paweł Zgódka, Paulina Steckiewicz, Marcin Pasiarski

Otrzymano/Received: 4.03.2019. Zaakceptowano/Accepted: 8.03.2019.

Cardiac complications during DLBCL treatment using R-CHOP

Cardiac complications during DLBCL treatment using R-CHOP OncoReview 2019; 1(33): 22-26. DOI: 10.24292/01.OR.119080319
STRESZCZENIE

Diffuse large B‐cell lymphoma (DLBCL) is the most frequent of non-Hodgkin’s lymphomas in the world. Immunochemotherapy with rituximab, doxorubicin, cyclophosphamide, vincristine, and prednisone (R‐CHOP) is the first-line treatment in this disease. Rituximab is a chimeric murine-human monoclonal anti-CD20 antibody, which binds specifically with CD20 receptor located on majority of mature B-cell lymphocytes. We are presenting the case of sudden cardiac arrest with ventricular fibrillation after intravenous injection of rituximab in a patient with DLBCL type NGC.

ABSTRACT

Diffuse large B‐cell lymphoma (DLBCL) is the most frequent of non-Hodgkin’s lymphomas in the world. Immunochemotherapy with rituximab, doxorubicin, cyclophosphamide, vincristine, and prednisone (R‐CHOP) is the first-line treatment in this disease. Rituximab is a chimeric murine-human monoclonal anti-CD20 antibody, which binds specifically with CD20 receptor located on majority of mature B-cell lymphocytes. We are presenting the case of sudden cardiac arrest with ventricular fibrillation after intravenous injection of rituximab in a patient with DLBCL type NGC.

POPRZEDNIE NUMERY